Shares of GoviEx Uranium Inc. (
CVE:GXU -
Get Free Report) dropped 3.8% on Thursday . The stock traded as low as C$0.05 and last traded at C$0.05. Approximately 480,300 shares traded hands during trading, a decline of 59% from the average daily volume of 1,167,044 shares. The stock had previously closed at C$0.05.
GoviEx Uranium Stock Performance
The firm has a market cap of C$51.10 million, a PE ratio of -5.00 and a beta of 1.82. The firm's 50-day moving average price is C$0.06 and its two-hundred day moving average price is C$0.06.
GoviEx Uranium Company Profile
(
Get Free Report)
GoviEx Uranium Inc, a mineral resources company, engages in the acquisition, exploration, and development of uranium properties in Africa. The company's principal asset is the Madaouela project which holds 80% interest located in north-central Niger. It also owns 100% interest in the Muntanga project that consists of 3 mining licenses situated to the south of Lusaka, Zambia; and the Falea project, which consists of three exploration licenses located in Mali.
Further Reading
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider GoviEx Uranium, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and GoviEx Uranium wasn't on the list.
While GoviEx Uranium currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.